• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Research Brief on 3-amino-1-phenylpropan-1-one (CAS: 2677-69-2): Recent Advances and Applications

3-amino-1-phenylpropan-1-one (CAS: 2677-69-2) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the development of central nervous system (CNS) therapeutics. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

Recent literature highlights the role of 3-amino-1-phenylpropan-1-one as a precursor in the synthesis of amphetamine derivatives and other psychoactive compounds. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its utility in the efficient synthesis of novel dopamine receptor agonists, which could have implications for treating Parkinson's disease and other neurological disorders. The study employed advanced spectroscopic techniques, including NMR and mass spectrometry, to characterize the compound and its derivatives, confirming their structural integrity and purity.

Another significant development involves the use of 3-amino-1-phenylpropan-1-one in the design of prodrugs. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibited enhanced bioavailability and targeted delivery to the CNS. The researchers utilized in vitro and in vivo models to evaluate the pharmacokinetic properties of these derivatives, revealing promising results for future clinical applications. These findings underscore the compound's versatility in medicinal chemistry.

In addition to its pharmacological potential, 3-amino-1-phenylpropan-1-one has also been investigated for its role in chemical biology. A recent preprint on ChemRxiv (2024) described its use as a fluorescent probe for detecting reactive oxygen species (ROS) in cellular environments. The study demonstrated that the compound's amino and carbonyl functional groups could be modified to produce sensitive and selective probes, offering new tools for studying oxidative stress in disease models.

Despite these advancements, challenges remain in the large-scale synthesis and regulatory approval of derivatives based on 3-amino-1-phenylpropan-1-one. Regulatory agencies have raised concerns about its structural similarity to controlled substances, necessitating rigorous safety and efficacy evaluations. Future research directions may focus on optimizing synthetic routes to improve yield and scalability, as well as conducting comprehensive toxicological studies to address regulatory requirements.

In conclusion, 3-amino-1-phenylpropan-1-one (CAS: 2677-69-2) continues to be a valuable scaffold in chemical biology and pharmaceutical research. Its applications range from CNS drug development to chemical probes, highlighting its multifaceted potential. Ongoing studies are expected to further elucidate its mechanisms of action and expand its utility in therapeutic and diagnostic contexts. Researchers and industry professionals should monitor this space for emerging developments and collaborative opportunities.

• 1688-71-7(4-Aminobutyrophenone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)